Bernstein reiterates Intuitive Surgical stock rating on strong growth By Investing.com

Intuitive Surgical delivered a strong Q1 2026 beat, with revenue of $2.77 billion (+23% y/y) versus $2.62 billion expected and EPS of $2.50 versus $2.12 consensus. Gross margin reached 67.8% and operating margin 38.9%, both ahead of estimates, while global da Vinci procedures rose 15.7% and management raised fiscal 2026 procedure and gross margin guidance. Bernstein reiterated Outperform with a $750 target, and other analysts remained constructive despite some valuation trims.

Analysis

ISRG is behaving like a high-quality compounder that is still underappreciated by the market’s earnings model: the real signal is not the beat itself, but the compounding of procedural growth, margin expansion, and a modestly better guide in the same print. That combination usually forces estimate revisions in two waves — first on headline EPS, then again as modelers raise medium-term procedure assumptions — which is why the stock can keep working for several months even after an initial gap up.

The second-order takeaway is that this is a pressure release valve for the broader med-tech group. If a premium-capital-intensity platform can absorb tariffs, hold utilization, and still widen margins, it weakens the bear case on elective-procedure sensitivity across robotics, imaging, and instruments. Competitively, that raises the bar for smaller robotic surgery aspirants: investors will increasingly pay for proof of installed-base monetization rather than “category growth” narratives, which should compress multiples for sub-scale peers that need heavier SG&A and product development spend to compete.

The key risk is valuation discipline, not operating execution. At this size and multiple, the stock likely needs either another quarter of clean upside or a visible acceleration in U.S. utilization to keep longs engaged; otherwise, it can become a “great company, fully owned” situation where upside is capped by rate-sensitive de-rating. The more durable bearish catalyst is any evidence that procedure growth normalizes into the low teens while shipments revert, because that would break the market’s assumption that da Vinci remains immune to macro noise.

Contrarianly, the market may be overfocusing on the tariff and guidance optics while underweighting mix and installed-base economics: a higher-procedure, higher-utilization environment can keep consumables and service revenue compounding even if capital placements are lumpy. That makes the stock less dependent on quarterly unit sales than it appears, and more dependent on whether the utilization inflection is real. If that holds, the next leg is likely driven by margin durability, not by another big beat on top-line consensus.

Key Decisions for Investors

• Stay long ISRG on pullbacks over the next 2-8 weeks; use any post-earnings consolidation as entry rather than chasing strength. Risk/reward remains favorable as long as estimates continue to ratchet higher and U.S. utilization stays positive.
• Pair trade: long ISRG / short a basket of smaller surgical robotics names or high-multiple med-tech laggards over 1-3 months. Thesis: leaders with proven installed-base monetization should outperform sub-scale names that need capital and time to catch up.
• Sell downside volatility via ISRG put spreads 1-2 quarters out if implied volatility remains elevated after the print. The setup favors gradual multiple support from revisions, while realized downside is likely limited absent a utilization surprise.
• For conservative portfolios, trim exposure only if the stock rallies into a valuation air pocket without follow-through in analyst upgrades over the next 30-45 days. That is the point where upside becomes more dependent on sentiment than fundamentals.